Global Hemophilia A Drug Market By Product Type (ATXF-8117, BAY-1093884) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-985537
  • April 2021
  • Pharmaceuticals
  • 141 Pages

Report Preview

The Hemophilia A Drug market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Hemophilia A Drug market research report recommends a business strategy for present market participants to strengthen their position in the market.

According to the report, the Hemophilia A Drug market size was USD xx million and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2020-2028. While considering the volume shipments the global Hemophilia A Drug market stood at xx (Units/Tons) in 2020 and expected to cross near about xx (units/Tons) by the end of forecast period.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Hemophilia A Drug market along with their effects over the forecast period. Similarly, according to the region Hemophilia A Drug market research report includes the study of opportunities available in the market situation.

The Hemophilia A Drug market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type ATXF-8117, BAY-1093884, BIVV-001, BS-027125, Concizumab, CSL-689, Others
Applications Clinic, Hospital, ASCs
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA

Global Hemophilia A Drug Market Segmentation by Regions:
In regional analysis, Hemophilia A Drug market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Hemophilia A Drug market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Hemophilia A Drug Market: Value and Forecast
  • U.S.
  • Canada
 
Europe Region for Hemophilia A Drug Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 
Asia Pacific Region for Hemophilia A Drug Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 
Latin America Region for Hemophilia A Drug Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 
Middle East and Africa for Hemophilia A Drug Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Global Hemophilia A Drug Market Segmentation by Type:
On the basis of product type, global Hemophilia A Drug market research report provides the production, revenue, price, and market share and growth rate of each type, primarily split into: ATXF-8117, BAY-1093884, BIVV-001, BS-027125, Concizumab, CSL-689, Others

Global Hemophilia A Drug Market Segmentation by Applications:
On the basis of the end users/applications, Hemophilia A Drug research report analyze the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including: Clinic, Hospital, ASCs

Major Key Players for Global Hemophilia A Drug Market:
The Hemophilia A Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA

Important Points Covered by Report:
  • To analyze the value of the Hemophilia A Drug market, according to the key region.
  • To study the Hemophilia A Drug market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Hemophilia A Drug market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Hemophilia A Drug research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Hemophilia A Drug market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Hemophilia A Drug market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Hemophilia A Drug market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Hemophilia A Drug market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Hemophilia A Drug market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Hemophilia A Drug Market Snapshot
          2.1.1. Global Hemophilia A Drug Market By Type,2019
               2.1.1.1.ATXF-8117
               2.1.1.2.BAY-1093884
               2.1.1.3.BIVV-001
               2.1.1.4.BS-027125
               2.1.1.5.Concizumab
               2.1.1.6.CSL-689
               2.1.1.7.Others
          2.1.2. Global Hemophilia A Drug Market By Application,2019
               2.1.2.1.Clinic
               2.1.2.2.Hospital
               2.1.2.3.ASCs
          2.1.3. Global Hemophilia A Drug Market By End-use,2019
          2.1.4. Global Hemophilia A Drug Market By Geography,2019

3. Global Hemophilia A Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028

5. Global Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028

6. Global Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Hemophilia A Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Hemophilia A Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Hemophilia A Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Hemophilia A Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Hemophilia A Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Hemophilia A Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Hemophilia A Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Hemophilia A Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Hemophilia A Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Hemophilia A Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Hemophilia A Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Hemophilia A Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Hemophilia A Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Hemophilia A Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Hemophilia A Drug Providers
        8.4.1 Bayer AG
                8.1.1 Business Description
                8.1.2 Bayer AG Geographic Operations
                8.1.3 Bayer AG Financial Information
                8.1.4 Bayer AG Product Positions/Portfolio
                8.1.5 Bayer AG Key Developments
        8.4.2 BioMarin Pharmaceutical Inc
                8.2.1 Business Description
                8.2.2 BioMarin Pharmaceutical Inc Geographic Operations
                8.2.3 BioMarin Pharmaceutical Inc Financial Information
                8.2.4 BioMarin Pharmaceutical Inc Product Positions/Portfolio
                8.2.5 BioMarin Pharmaceutical Inc Key Developments
        8.4.3 Bioverativ Inc
                8.3.1 Business Description
                8.3.2 Bioverativ Inc Geographic Operations
                8.3.3 Bioverativ Inc Financial Information
                8.3.4 Bioverativ Inc Product Positions/Portfolio
                8.3.5 Bioverativ Inc Key Developments
        8.4.4 Catalyst Biosciences Inc
                8.4.1 Business Description
                8.4.2 Catalyst Biosciences Inc Geographic Operations
                8.4.3 Catalyst Biosciences Inc Financial Information
                8.4.4 Catalyst Biosciences Inc Product Positions/Portfolio
                8.4.5 Catalyst Biosciences Inc Key Developments
        8.4.5 Chugai Pharmaceutical Co Ltd
                8.5.1 Business Description
                8.5.2 Chugai Pharmaceutical Co Ltd Geographic Operations
                8.5.3 Chugai Pharmaceutical Co Ltd Financial Information
                8.5.4 Chugai Pharmaceutical Co Ltd Product Positions/Portfolio
                8.5.5 Chugai Pharmaceutical Co Ltd Key Developments
        8.4.6 CSL Ltd
                8.6.1 Business Description
                8.6.2 CSL Ltd Geographic Operations
                8.6.3 CSL Ltd Financial Information
                8.6.4 CSL Ltd Product Positions/Portfolio
                8.6.5 CSL Ltd Key Developments
        8.4.7 DBV Technologies SA
                8.7.1 Business Description
                8.7.2 DBV Technologies SA Geographic Operations
                8.7.3 DBV Technologies SA Financial Information
                8.7.4 DBV Technologies SA Product Positions/Portfolio
                8.7.5 DBV Technologies SA Key Developments
        8.4.8 Dimension Therapeutics Inc
                8.8.1 Business Description
                8.8.2 Dimension Therapeutics Inc Geographic Operations
                8.8.3 Dimension Therapeutics Inc Financial Information
                8.8.4 Dimension Therapeutics Inc Product Positions/Portfolio
                8.8.5 Dimension Therapeutics Inc Key Developments
        8.4.9 EpiVax Inc
                8.9.1 Business Description
                8.9.2 EpiVax Inc Geographic Operations
                8.9.3 EpiVax Inc Financial Information
                8.9.4 EpiVax Inc Product Positions/Portfolio
                8.9.5 EpiVax Inc Key Developments
        8.4.10 Expression Therapeutics LLC
                8.10.1 Business Description
                8.10.2 Expression Therapeutics LLC Geographic Operations
                8.10.3 Expression Therapeutics LLC Financial Information
                8.10.4 Expression Therapeutics LLC Product Positions/Portfolio
                8.10.5 Expression Therapeutics LLC Key Developments
        8.4.11 Green Cross Corp
                8.11.1 Business Description
                8.11.2 Green Cross Corp Geographic Operations
                8.11.3 Green Cross Corp Financial Information
                8.11.4 Green Cross Corp Product Positions/Portfolio
                8.11.5 Green Cross Corp Key Developments
        8.4.12 Idogen AB
                8.12.1 Business Description
                8.12.2 Idogen AB Geographic Operations
                8.12.3 Idogen AB Financial Information
                8.12.4 Idogen AB Product Positions/Portfolio
                8.12.5 Idogen AB Key Developments
        8.4.13 Immusoft Corp
                8.13.1 Business Description
                8.13.2 Immusoft Corp Geographic Operations
                8.13.3 Immusoft Corp Financial Information
                8.13.4 Immusoft Corp Product Positions/Portfolio
                8.13.5 Immusoft Corp Key Developments
        8.4.14 LFB SA
                8.14.1 Business Description
                8.14.2 LFB SA Geographic Operations
                8.14.3 LFB SA Financial Information
                8.14.4 LFB SA Product Positions/Portfolio
                8.14.5 LFB SA Key Developments
        8.4.15 mAbxience SA
                8.15.1 Business Description
                8.15.2 mAbxience SA Geographic Operations
                8.15.3 mAbxience SA Financial Information
                8.15.4 mAbxience SA Product Positions/Portfolio
                8.15.5 mAbxience SA Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Hemophilia A Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Hemophilia A Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Hemophilia A Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Hemophilia A Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Hemophilia A Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Hemophilia A Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Hemophilia A Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Hemophilia A Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Hemophilia A Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Hemophilia A Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Hemophilia A Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Hemophilia A Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Hemophilia A Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Hemophilia A Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Hemophilia A Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Hemophilia A Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Hemophilia A Drug: Market Segmentation 
FIG. 2 Global Hemophilia A Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Hemophilia A Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Hemophilia A Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Hemophilia A Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Hemophilia A Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Hemophilia A Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Hemophilia A Drug Providers, 2019
FIG. 11 Global Hemophilia A Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Hemophilia A Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Hemophilia A Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Hemophilia A Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Hemophilia A Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Hemophilia A Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Hemophilia A Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Hemophilia A Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Hemophilia A Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Hemophilia A Drug Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Hemophilia A Drug Market Value, By Segment1, 2018 – 2028
TABLE  North America Hemophilia A Drug Market Value, By Segment2, 2018 – 2028
TABLE  North America Hemophilia A Drug Market Value, By Country, 2018 – 2028
TABLE  Europe Hemophilia A Drug Market Value, By Segment1, 2018 – 2028
TABLE  Europe Hemophilia A Drug Market Value, By Segment2, 2018 – 2028
TABLE  Europe Hemophilia A Drug Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Hemophilia A Drug Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Hemophilia A Drug Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Hemophilia A Drug Market Value, By Country, 2018 – 2028
TABLE  Latin America Hemophilia A Drug Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Hemophilia A Drug Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Hemophilia A Drug Market Value, By Country, 2018 – 2028
TABLE  MEA Hemophilia A Drug Market Value, By Segment1, 2018 – 2028
TABLE  MEA Hemophilia A Drug Market Value, By Segment2, 2018 – 2028
TABLE  MEA Hemophilia A Drug Market Value, By Country, 2018 – 2028
TABLE  Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  BioMarin Pharmaceutical Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bioverativ Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Catalyst Biosciences Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Chugai Pharmaceutical Co Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CSL Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  DBV Technologies SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dimension Therapeutics Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  EpiVax Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Expression Therapeutics LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Green Cross Corp: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Idogen AB: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Immusoft Corp: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  LFB SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  mAbxience SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Hemophilia A Drug Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Hemophilia A Drug Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Hemophilia A Drug Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Hemophilia A Drug Market, By Geography, 2019 (US$ Mn)
FIG.  Global Hemophilia A Drug Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Hemophilia A Drug Providers, 2016
FIG.  Global Hemophilia A Drug Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global ATXF-8117 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global BAY-1093884 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global BIVV-001 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global BS-027125 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Concizumab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global CSL-689 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hemophilia A Drug Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global ASCs Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Hemophilia A Drug Market Value, 2018 – 2028, (US$ Mn)